For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
GHRP-6 is the original growth hormone releasing peptide, synthesized by Cyril Bowers and colleagues at Tulane University in 1984 as the first synthetic peptide to specifically and dose-dependently release GH through a receptor mechanism entirely distinct from GHRH. Its pharmacological characterization generated the field of GH secretagogue research, identified GHS-R1a as a receptor class, and ultimately enabled the discovery of ghrelin in 1999. Human Phase 1 data from Bowers et al. (1990, n=18) established dose-dependent GH release: mean peak GH of 68.7 plus or minus 15.5 mcg/L at 1.0 mcg/kg IV. GHRP-6's defining clinical characteristic is its stronger appetite stimulation than any other GHRP -- a pharmacological certainty from GHS-R1a activation, not an individual side effect. It has been superseded for most applications by ipamorelin (cleaner endocrine profile) and GHRP-2 (greater GH potency), but remains the historically foundational compound of the class.
The complete GHRP-6 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use